[ Home ] [ Controlled Substances ] [ Stimulants ]
NEA
|
Etilamfetamine (Apetinil) is a stimulant drug of amphetamine chemical class. It is an N-substituted amphetamine with an ethyl group on the amphetamine backbone. It was used as an anorectic or appetite suppressant. Etilamfetamine is a psychoactive drug, which can be used as a recreational drug. Etilamfetamine has been abused as a "designer drug" alternative to amphetamine and possibly methamphetamine. It is a dopamine releasing agent.
Etilamfetamine (Apetinil):
https://drugs.ncats.io/drug/022YON1XMX
https://www.caymanchem.com/msdss/11557m.pdf
It was invented in the early 20th century and was subsequently used as an anorectic or appetite suppressant in the 1950s, but was not as commonly used as other amphetamines. was largely discontinued once newer drugs such as phenmetrazine were introduced. It most likely acts primarily as a dopamine releasing agent. Its activity as a norepinephrine or serotonin releasing agent is not known. Ethylamphetamine can be used as a recreational drug and, while its prevalence is less than amphetamine's, it is still encountered as a substance taken for recreational purposes. Ethylamphetamine produces effects similar to amphetamine and methamphetamine, though its potency is less. At equipotent dosage, ethylamphetamine is subjectively less euphorigenic.
Multidisciplinary Infrastructure Streamlines Cancer Care During Drug Shortages - The establishment of a multidisciplinary committee can help identify opportunities to best face the ongoing cancer drug shortage. Thursday April 25, 2024 - oncnursingnews.com New AI drug discovery powerhouse Xaira rises with $1B in funding - If you asked an AI to generate a brand-new drug discovery biotech with a team of some of the biggest names in the biz for you, it couldn’t dream up one like Xaira Therapeutics. | If you asked an AI to ... AI Drug Developer Xaira Therapeutics Launches with $1B+ - At Genentech, Rajpal established the large molecule drug discovery (LMDD) organization consisting of ... Capital led the billion-dollar-plus financing, joined by F-Prime, NEA, Sequoia Capital, Lux ... Enter Xaira, with $1bn for its AI in drug discovery platform - The San Francisco-based company has emerged from the incubators of ARCH Venture Partners and Foresite Labs with more than $1 billion in funding to develop AI technologies nurtured in the lab of ... Xaira, an AI drug discovery startup, launches with a massive $1B, says it's 'ready' to start developing drugs - Advances in generative AI have taken the tech world by storm. Biotech investors are making a big bet that similar computational methods could revolutionize drug discovery. On Tuesday, ARCH Venture ... Ex-Stanford president's AI biotech startup snares $1 billion - Xaira Therapeutics, an AI drug discovery startup, has launched with more than $1 billion in funding co-led by Arch Venture Partners and Foresite Ventures. Why it matters: Xaira is the landing spot for ... Backed by $1 billion, Xaira Therapeutics is readying AI-generated drugs - And for the last eight months, Kamisetty has been leading artificial intelligence and machine learning efforts at a new start-up called Xaira Therapeutics, which formally launched Tuesday with $1 ... Nuveen AMT-Free Quality Muni Inc NEA - We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ... Nuveen AMT-Free Quality Municipal Income Fund (NEA) - NEA) announce the removal of a previously approved merger proposal from each funds’ upcoming shareholder meeting agenda. Previously, the Board of Trustees of each respective fund approved the ... Drug Enforcement Administration holding Drug Take Back Day this weekend - The Drug Enforcement Administration is hosting the 26th Prescription Drug Take Back Day this Saturday around the United States.The bi-annual event offers free, anonymous disposal of unneeded ... AI-Powered Xaira Launches with $1B, Ex-Genentech Execs Look to Transform R&D - Xaira Therapeutics emerged from stealth on Wednesday with plans to tap the biological equivalent of artificial intelligence image generation tools designed to create molecules that hit hard-to-drug ...
| ||
| Stimulants | Link to this page |